Dronedarone: An anniodarone analog for the treatment of atrial fibrillation and atrial flutter

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 599-605

  Dale, Krista M ^a,b   White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Atrial flutter; Dronedarone

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DOFETILIDE; DRONEDARONE; FLECAINIDE; GLYCOPROTEIN P; GUANYLATE CYCLASE; LIOTHYRONINE; METOPROLOL; NITRIC OXIDE SYNTHASE; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROPAFENONE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; THYROTROPIN; THYROXINE; UNINDEXED DRUG; VASODILATOR AGENT; DRUG DERIVATIVE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN DISCOLORATION; THYROID DISEASE; TORSADE DES POINTES; VOMITING; ANIMAL; BIOAVAILABILITY; DRUG INTERACTION; HALF LIFE TIME;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DRUG INTERACTIONS; HALF-LIFE; HUMANS;

EID: 34247235590     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H524     Document Type: Review

References (29)

1. Thorn T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:85-151.
2. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003; 91:15D-26D.
3. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today 2006;42:75-86.
4. Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart. Eur J Pharmacol 2004;496:119-27.
5. Aimond F, Beck L, Gautier P, et al. Cellular and in vivo electrophysiological effects of dronedarone in normal and post myocardial infracted rats. J Pharmacol Exp Ther 2000;292:415-24.
6. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999;100:2276-81.
7. Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 2002;39:677-84.
8. Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Charelain P. SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol 1995;25: 252-61.
9. Touboul P, Brugada J, Capacci A, Crijns H, Edvardsson N, Hohnloser S. Dronedarone for prevention of atrial fibrillation: a dose ranging study. Eur Heart J 2003;24:1481-7.
10. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoreceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol 1995;279:25-32.
11. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative reserach on dofetilide (SAFIRE-D) study. Circulation 2000;102: 22385-90.
12. Pritchett EL, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3). J Am Coll Cardiol 2000;36:794-802.
13. Connolly SJ, Roy D. Randomized trials of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter: EURIDIS and ADONIS. Can J Cardiol 2004;20:197D-8D.
14. Schellekens S, Verheught FW. Hotline sessions of the 26th European Congress of Cardiology. Eur Heart J 2004;25:2164-6.
15. Singh BN, Hohnloser SH, Connolly SJ, et al. The EURIDIS and ADONIS trials: dronedarone for maintaining sinus rhythm in patients with atrial fibrillation/flutter (abstract 3429). Circulation 2004;110(suppl III):741.
16. Davy JM. Dronedarone demonstrates additional rate control on top of standard pharmacotherapies in the treatment of atrial fibrillation (abstract 2737). Presented at: American Heart Association 2005 Scientific Sessions, Dallas, November 13-16, 2005.
17. European Medicines Agency. Evaluation of medicines for human use: withdrawal public assessment report of the marketing authorization application for MULTAQ (dronedarone). www.emea.eu.int/humandocs/PDFs/EPAR/multaq/361489en. pdf (accessed 2006 Oct 31).
18. US National Institutes of Health Clinical Trial Registration. ATHENA: a trial with dronedarone to prevent hospitalization or death in patients with atrial fibrillation. www.clinicaltrials.gov/ct/show/NCT00174785 (accessed 2006 Aug 1).
19. Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR33589, in comparison to amiodarone, D, L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1995;26:570-6.
20. Manning AS, Bruyninckx C, Ramboux J, Chatelain P. SR33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995;26:453-61.
21. Kowey P. Preliminary data show dronedarone safer alternative to amiodarone. Late-breaking clinical trial session at the 25th Annual Session of the Heart Rhythm Society, San Francisco, May 19-22, 2004.
22. Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol 2004;287:L438-47.
23. Pantos C, Mourouzis I, Delbruyere M, et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and post ischemic performance of the isolated rat heart. Eur J Pharmacol 2002; 444:191-6.
24. Van Beeren HC, Jong WM, Kaptein E, Visser TH, Bakker O, Wiersinga WM. Dronedarone acts as a selective inhibitor of 3,5,3′-triiodothyronine binding to thyroid hormone receptor-alpha 1: in vitro and in vivo evidence. Endocrinology 2003;144:552-8.
25. Van Opstal JM, Schoenmakers M, Cerduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104:2722-7.
26. Ventricular Arrhythmias and Sudden Cardiac Death: ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol 2006;48:1064-108.
27. Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004;18:113-23.
28. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs of Today 2006;42:75-86.
29. Fluster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:e257-e354.